Navigation Links
ExonHit Builds A New Organisation
Date:1/16/2008

PARIS, January 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that it has created two commercial business units: the Molecular Diagnostics and Genomic Services Unit and the Therapeutics Unit.

The accomplishments of the last years and recent progress in core programs have laid the foundation to implement a new structure more targeted to the market. John Jaskowiak has been appointed as Head of the Molecular Diagnostics and Genomic Services Unit and Matt Pando has been appointed as Head of the Therapeutics Unit. In addition, the company has recruited two new collaborators: Anders Ingvarsson as Vice-President of Marketing of Molecular Diagnostics and James Douglas as Vice-President of Corporate Strategy and Projects. This organization will receive support from the Financial Department headed by Philippe Rousseau and the Legal Department headed by Frederique Schlumberger.

Anders Ingvarsson is Swedish and has a dual academic background in Chemical Engineering and Marketing. He has been instrumental in launching start-up companies and developing diagnostics distribution channels in Europe. He worked from 2001 to 2007 for Sangtec Molecular Diagnostics as Executive Vice President, achieving key collaborations and partnerships with major diagnostics companies, before creating his own consulting firm in Stockholm in 2007. He will be responsible for the design and implementation of marketing plans for ExonHit Therapeutics diagnostic products.

James Douglas was previously Senior Vice President, Sales and Marketing of the German diagnostic company, Epigenomics. Previous to Epigenomics, Mr. Douglas was Vice President, Sales and Marketing for Biosite where he was responsible for the launch of the cardiovascular diagnostic, BNP. He also served as Vice President, Marketing for Gen-Probe, was Director of Marketing at Centocor and held sales and marketing positions with Sanofi Diagnostics Pasteur a
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. ExonHit and bioMerieux Amend Their Strategic Partnership
2. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
3. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
4. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, owing to the launches of ... will increase more than sevenfold from $790 million ... the United States, France, Germany, Italy, Spain, the ... report entitled Atrial Fibrillation finds that ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
(Date:12/11/2009)... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... Alan Warrander to the role of Senior Vice ... Warrander will be responsible for the execution of ... Brad Thompson, President and CEO of Oncolytics. "Having ... Phase 3 trial examining REOLYSIN in combination with ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... Scientists at the Albert Einstein College of Medicine of ... transplanted cells can cure hemophilia A (the most common ... study appears online February 14 in the Journal of ... males and is characterized by recurrent, spontaneous bleeding that ...
... of the National Nanotechnology Initiative (NNI) Fiscal Year 2009 ... and Technology (NSET) Subcommittee of the National Science and ... supplement to the Presidents Budget for Fiscal Year 2009, ... well as highlights of planned activities to be conducted ...
... Sigma-Aldrich and Atlas Antibodies Establish Exclusive Distribution ... ... (Nasdaq:,SIAL) today announced an exclusive partnership with Atlas Antibodies to,distribute Prestige ... and cell biology research communities.,Initially consisting of 1800 antibodies, the library ...
Other Biology Technology:Transplanted cells may hold the key to curing hemophilia A, Einstein scientists report 2National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights 2Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers 2Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers 3
(Date:12/14/2009)... In support of the United Nations Framework Convention ... European Environment Agency hosted the ,Bend the Trend, ... climate networking platform and premiere the screening of ... ,Environmental Atlas of Europe, a joint project of ... Programme (UNEP) and ESA, is a series of ...
(Date:12/13/2009)... have identified plant enzymes that may help to engineer ... use water more efficiently. The finding could help to ... , Plants take in the carbon dioxide they need ... of leaves. But for each molecule of the gas ... same openings. The pores can tighten to save water ...
(Date:12/13/2009)... Scientists have discovered five genetic variants that are associated ... by an international consortium of 96 scientists from 63 ... the molecular basis of lung diseases. , The new ... like Chronic Obstructive Pulmonary Disease (COPD) and asthma. In ... treatments because the molecular pathways that affect the health ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3New genes for lung disease discovered 2Cancer Survivors Share The Day I Found Out 28TM 29 58807 1Cancer Survivors Share The Day I Found Out 28TM 29 58807 2CORRECTION 3A Celebrate Your Family 58803 1CORRECTION 3A Celebrate Your Family 58803 2CORRECTION 3A Celebrate Your Family 58803 3CORRECTION 3A Celebrate Your Family 58803 4University Hospitals Case Medical Center earns prestigious national award for excellence 58801 1University Hospitals Case Medical Center earns prestigious national award for excellence 58801 2
... the Department of Energy,s Oak Ridge National Laboratory and ... developing nerve cells may hold a key to predicting ... disease. , St. Jude scientists have linked movement and ... and retinas of young mice to certain diseases. Now, ...
... discovered that cane toads are far more susceptible to being ... research published in the British Ecological Society,s journal ... toad,s armour that could help control the spread of this ... and his colleagues Georgia Ward-Fear, Matt Greenlees and Greg Brown ...
... new, environmentally friendly coating that protects metals against ... team of researchers from Sheffield Hallam University. At ... today, (Monday 30 March), Jeanette Gittens and colleagues ... bacterium into a sol-gel coating which then protected ...
Other Biology News:ORNL, St. Jude track neurons to predict and prevent disease 2Aussie meat ants may be invasive cane toad's Achilles' heel 2